Related Experiment Video
Updated: Oct 22, 2025

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial
Chiara Agrati1, Serena Di Cosimo2, Daniela Fenoglio3,4
1Cellular Immunology Laboratory, Department of Epidemiology, Preclinical Research and Advanced Diagnostic, National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani - IRCCS, Roma, Italy.
Abstract:
Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases.
Related Concept Videos
Vaccinations
Bioavailability Study Design: Healthy Subjects Versus Patients
Clinical Trials: Overview
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Microorganisms in Medicine and Therapeutics

